Printer Friendly

GENSIA LABORATORIES RECEIVES ANDA APPROVALS FOR INJECTABLE ANTI-INFECTIVE AND ADJUNCT TO CHEMOTHERAPY

 SAN DIEGO, Sept. 30 /PRNewswire/ -- Gensia Inc. (NASDAQ: GNSA) today announced that Gensia Laboratories Ltd. (a wholly owned subsidiary of Gensia Inc.) has received approval of three Abbreviated New Drug Applications (ANDAs) from the Food and Drug Administration (FDA) to market amikacin sulfate in three sizes and leucovorin calcium in two sizes for injection. With these three approvals, Gensia Laboratories now has 23 approved ANDAs covering 18 multisource (generic) drugs, according to David F. Hale, chairman, president, and chief executive officer of Gensia Inc.
 Amikacin sulfate is an anti-infective used in hospitals for the treatment of Gram-negative and staphylococcal infections. Leucovorin calcium is an adjunct to chemotherapy, used to mediate the toxicity associated with high doses of methotrexate and with certain other chemotherapeutic agents. Gensia Laboratories will manufacture and market both products in the United States.
 "This is Gensia Laboratories' first significant entry into the anti- infective and oncology market as part of our strategy to distribute acute-care multisource products in the fields of anti-infectives, cardiology, anesthesiology, and oncology," said Hale. "We hope to receive ANDA approvals for two additional major multisource products."
 Gensia Laboratories Ltd. is located in Irvine, Calif., and develops, manufactures, and markets multisource injectable drug products for the acute-care hospital market.
 Gensia Inc. is a San Diego-based biopharmaceutical company formed to discover, develop, manufacture, and market novel pharmaceutical products for the treatment and diagnosis of human diseases.
 -0- 9/30/93
 /CONTACT: Elizabeth A. Gard, Gensia Inc., 619-546-8300/
 (GNSA)


CO: Gensia Inc.; Gensia Laboratories Ltd. ST: California IN: MTC SU:

MF-LS -- SD002 -- 7136 09/30/93 09:02 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 30, 1993
Words:263
Previous Article:ASHLAND COAL, INC. REPORTS THIRD QUARTER TAX EFFECTS
Next Article:SOLECTRON COMPLETES PURCHASE OF PHILIPS' SCOTTISH CONTRACT ASSEMBLIES BUSINESS
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters